2. Anti-infection
  3. Influenza Virus
  4. Lesofavumab

Lesofavumab  (Synonyms: MHAB5553A; RG70026)

目录号: HY-P99699 纯度: 98.27%
COA

摩尔计算器

Lesofavumab (MHAB5553A) 是一种人 IgG1κ 抗 influenza B virus 抗体。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Lesofavumab Chemical Structure

Lesofavumab Chemical Structure

CAS No. : 1807960-57-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥3000
In-stock
5 mg ￥7800
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Customer Review

Lesofavumab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1].

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Human
IC50 & Target

Influenza B virus[1]
体外研究
(In Vitro)

Lesofavumab (MHAB5553A) 与血凝素 (HA) 残留酯酶结构域的一个保守表位结合，血凝素是 B 型流感病毒上的一种主要免疫显性表面糖蛋白，并在内体中阻断 HA 介导的膜融合[1]。
Lesofavumab (46B8) 能够中和所有 11 种与 >70 年人类感染相关的 IBV 菌株，IC50 值范围为 0.58-0.95 nM[2]。
Lesofavumab (46B8; 0-100 ng/mL) 在体外阻断膜融合并诱导抗体依赖性细胞毒性 (ADCC)[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Lesofavumab 相关抗体:
体内研究
(In Vivo)

Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) 能够保护小鼠免受突变型 B 型流感病毒的致命性[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DBA/2 J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2]
Dosage: 15 mg/kg
Administration: Intravenous administration, single dose, 24, 48 or 72 h post infection
Result: Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48 h. Even when given at 72 h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

来索伏单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料

纯度: 98.27%

COA (172 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Lesofavumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lesofavumab1807960-57-1MHAB5553A RG70026来索伏单抗RG70026RG 70026RG-70026Influenza VirushemagglutininIBVDBA/2?J miceADCCantibody-dependent cellular cytotoxicityInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Lesofavumab
目录号：
HY-P99699
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z